Molecular docking and in vivo evaluation of luteolin as apotential egfr inhibitor in an experimental tumor model
Cancer remains one of the leading causes of mortality worldwide, and the overexpression of Epidermal Growth Factor Receptor (EGFR) plays a critical role in tumor progression, proliferation, angiogenesis, and metastasis. The present study aimed to investigate the anticancer potential of luteolin, a naturally occurring flavonoid, through molecular docking and in vivo experimental tumor evaluation targeting EGFR. Molecular docking studies were performed to evaluate the binding affinity and interaction of luteolin with the active site of EGFR protein.